Vident Investment Advisory LLC Has $6.20 Million Position in Gilead Sciences, Inc. (GILD)
Vident Investment Advisory LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.8% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 87,509 shares of the biopharmaceutical company’s stock after buying an additional 12,581 shares during the quarter. Vident Investment Advisory LLC’s holdings in Gilead Sciences were worth $6,199,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in GILD. Archford Capital Strategies LLC purchased a new stake in shares of Gilead Sciences during the 1st quarter valued at about $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $132,000. Brand Asset Management Group Inc. purchased a new stake in Gilead Sciences during the 2nd quarter worth approximately $139,000. Stelac Advisory Services LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $141,000. Finally, Vivaldi Capital Management LLC purchased a new stake in Gilead Sciences during the 1st quarter worth approximately $206,000. Institutional investors and hedge funds own 78.04% of the company’s stock.
In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 2nd. The stock was sold at an average price of $70.81, for a total value of $3,540,500.00. Following the completion of the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $217,228,227.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last quarter, insiders sold 150,000 shares of company stock valued at $11,141,000. Insiders own 1.16% of the company’s stock.
Shares of GILD opened at $74.64 on Wednesday. The company has a market capitalization of $93.62 billion, a PE ratio of 8.68, a PEG ratio of -5.50 and a beta of 1.02. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23. Gilead Sciences, Inc. has a 52 week low of $64.27 and a 52 week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.56 by $0.35. The company had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The business’s revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the firm earned $2.56 EPS. equities analysts expect that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.05%. Gilead Sciences’s payout ratio is 26.64%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: What is the Book Value of a Share?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.